Investment
Features
FeesSafety
Academy
More
Pluang+

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

Market News
18 Sep 2026
Crypto news
View Source
Bullish
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's 50%, allowing users more borrowing capacity. This new feature, running on HyperCore infrastructure, lets users choose borrowing amounts manually, with interest rates based on liquidity usage. Hyperliquid's growing product range includes plans for regulated perpetual futures markets for U.S. clients, signaling expansion and increased adoption potential.

HYPE token price action is the subject, with Pluang market data as context. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 18, 2026 22:51 WIB: out of 50 major cryptocurrencies priced on Pluang, 45 rose and 4 fell today. Notable movers include UNI (Uniswap) at Rp155.937 with a 21.11% increase, THETA (Theta Network) at Rp3.636 with an 11.98% rise, and BAL (Balancer) at Rp16.297 up 11.14%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
Micron's stock soars 500% in a year amid record earnings but faces mixed analyst views on future growth.

Micron's stock soars 500% in a year amid record earnings but faces mixed analyst views on future growth.

Micron Technology's shares have surged over 500% in the past 12 months, driven by a strong memory super-cycle and record fiscal Q3 2026 results, including $41.5 billion revenue and 84.6% gross margin. Despite this, the stock recently dipped as invest...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App